<DOC>
	<DOCNO>NCT01687218</DOCNO>
	<brief_summary>MTN-017 Phase 2 , multi-site , randomize , six-sequence , two three-period , open label crossover study , examine effect oral Truvada reduce glycerin 1 % tenofovir gel . The study population sexually active , HIV-uninfected male 18 year age old , report history receptive anal intercourse past 3 month . Each study product regimens offer different advantage participant seek effective HIV prevention agent . How relative advantage compare term safety , acceptability , systemic local absorption , adherence examine within study .</brief_summary>
	<brief_title>Safety Acceptability Study Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet Rectally-Applied Tenofovir Reduced-Glycerin 1 % Gel</brief_title>
	<detailed_description />
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Glycerol</mesh_term>
	<criteria>1 . Male transgender female &gt; age 18 Screening 2 . Able willing provide write informed consent 3 . HIV1 uninfected Screening Enrollment 4 . Able willing provide adequate locator information , define site SOP 5 . Available return study visit , bar unforeseen circumstance willing comply study participation requirement 6 . In general good health Screening Enrollment , determine site IoR designee 7 . Per participant report , history consensual RAI least past 3 month 8 . Per participant report Screening Enrollment , agree engage receptive insertive sexual activity another study participant duration study participation . 9 . Willing use studyprovided condom duration study penetrative intercourse 10 . Willing take part research study involve drug , medical device , vaccine genital product duration study participation ( include time Screening Enrollment ) 11 . Men transgender female agree take part PK , PD Mucosal Immunology Subset , must also agree abstain : Inserting anything rectum , include abstain RAI 72 hour collection biopsy Taking nonsteroidal antiinflammatory drug ( NSAIDs ) , aspirin and/or drug associate increase likelihood bleeding follow mucosal biopsy collection 72 hour prior follow collection biopsy . 1 . At Screening , participantreported symptom , and/or clinical laboratory diagnosis active anorectal reproductive tract infection require treatment per current World Health Organization ( WHO ) guideline symptomatic urinary tract infection ( UTI ) . Infections require treatment include symptomatic Chlamydia trachomatis ( CT ) infection , Neisseria gonorrhea ( GC ) , syphilis , active herpes simplex virus ( HSV ) lesion , anogenital sore ulcer , symptomatic genital wart . Note : HSV1 HSV2 seropositive diagnosis active lesion allow , since treatment require . In case nonanorectal GC/CT identify screening , one rescreening 2 month screen visit allow 2 . History inflammatory bowel disease report participant history 3 . At Screening : Positive hepatitis B surface antigen Positive hepatitis C antibody Hemoglobin &lt; 10.0 g/dL Platelet count le 100,000/mm3 White blood cell count &lt; 2,000 cells/mm3 &gt; 15,000 cells/mm3 Calculated creatinine clearance le 60 mL/min CockcroftGault formula creatinine clearance mL/min = ( 140 age year ) x ( weight kg ) x ( 1 male ) /72 x ( serum creatinine mg/dL ) Serum creatinine &gt; 1.3 x site laboratory upper limit normal ( ULN ) Alanine transaminase ( ALT ) and/or aspartate aminotransferase ( AST ) &gt; 2.5× site laboratory ULN PK , PD Immunological Subset : International normalized ratio ( INR ) &gt; 1.5× site laboratory ULN partial thromboplastin time ( PTT ) &gt; 1.25× site laboratory ULN 4 . Known allergy methylparaben and/or propylparaben 5 . Known allergy study product . 6 . Per participant report , use follow medication and/or product within 12 week prior screen , and/or anticipate use unwillingness abstain use throughout study participation : Any investigational product Systemic immunomodulatory medication Use Heparin , include Lovenox® Warfarin Plavix® ( clopidogrel bisulfate ) Rectallyadministered medication product , contain N9 corticosteroid 7 . By participant report , use postexposure prophylaxis ( PEP ) HIV exposure within 12 week prior screen anticipate use study participation . 8 . Symptoms suggestive acute HIV seroconversion Screening Enrollment 9 . Has condition , opinion IoR/designee , would preclude informed consent , make study participation unsafe , complicate interpretation study outcome data , otherwise interfere achieve study objective would make patient unsuitable study unable/unwilling comply study requirement . Such condition may include , limited , colorectal abnormality , substance abuse , renal , hepatic , hematological , gastrointestinal , endocrine , pulmonary , neurological psychiatric disease .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>